Literature DB >> 15350327

Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy.

Tarun Sharma1, Nitant Shah, Madhav Rao, Lingam Gopal, Mahesh P Shanmugam, Mahesh Gopalakrishnan, Pramod Bhende, Muna Bhende, Nitin S Shetty, Sukumar Baluswamy.   

Abstract

PURPOSE: To elucidate the effect of discontinuation of corticosteroids in patients with atypical severe central serous chorioretinopathy (CSC) on retinal reattachment, resolution of retinal pigment epithelium (RPE) leaks, and improvement in visual acuity (VA).
DESIGN: Prospective, noncomparative, observational case series. PARTICIPANTS: Twenty-four eyes of 17 patients who were being treated with corticosteroids for atypical severe CSC. Of these 17 patients, 16 were treated inappropriately with corticosteroids for their ocular condition; presumably, these patients' conditions were misdiagnosed, and they were thought to have choroiditis, Harada's syndrome, or similar entities, and not central serous chorioretinopathy. INTERVENTION: Observation or laser photocoagulation. MAIN OUTCOME MEASURES: Reattachment of the retina, obliteration of RPE leaks on fundus fluorescein angiography, and improvement in Snellen VA.
RESULTS: Discontinuation of corticosteroids resulted in reattachment of the retina in 21 eyes (87.5%), with median time to reattachment of 49 days (range, 32-400); only 3 eyes required laser photocoagulation. Fundus fluorescein angiography showed obliteration of RPE leaks at a median period of 75 days (range, 32-400) in the observed eyes; the median VA improved from 20/80 to 20/30. The mean follow-up was 16.5 months.
CONCLUSIONS: Discontinuation of corticosteroids in atypical CSC helped in obliteration of RPE leaks and retinal reattachment in 87.5% of the eyes without laser treatment, and improvement in VA was observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350327     DOI: 10.1016/j.ophtha.2004.03.025

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  Corticosteroid-associated atypical central serous chorioretinopathy in a patient with multiple sclerosis.

Authors:  Mahmut Kaya; Derya Kaya; Egemen Idiman
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

Review 3.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 4.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

5.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

6.  Association of Corticosteroid Use With Incidence of Central Serous Chorioretinopathy in South Korea.

Authors:  Tyler Hyungtaek Rim; Hee Suk Kim; Jiyong Kwak; Jihei Sara Lee; Dong Wook Kim; Sung Soo Kim
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

Review 7.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

8.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

9.  The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.

Authors:  Ji Won Lim; Su Jeong Ryu; Min Cheol Shin
Journal:  Korean J Ophthalmol       Date:  2010-06-05

Review 10.  Pachychoroid disease.

Authors:  Chui Ming Gemmy Cheung; Won Ki Lee; Hideki Koizumi; Kunal Dansingani; Timothy Y Y Lai; K Bailey Freund
Journal:  Eye (Lond)       Date:  2018-07-11       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.